The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with ...

This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure ...

08 July 2025 via Zoom Final Agenda The meeting will take place via Zoom, a secure web conferencing tool. The meeting will run from 9:00am although this may be subject to change. Joining links and ...

Recognise that people under 16 with suspected sepsis are at moderate to high risk of severe illness or death from sepsis if they meet any of the moderate to high risk criteria: For children under 5, ...

On this page 1.1 Detection in primary care 1.2 Establishing the diagnosis in secondary care 1.3 Information and support for women with newly diagnosed ovarian cancer 1.4 Management of suspected early ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. Commercial arrangement There is a ...

In development [GID-TA11183] Expected publication date: 02 July 2025 ...